Eszter Csomor

Granta Park
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial.

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: August 08, 2025

Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial.

Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial.

Journal: RMD open

Published: May 20, 2025

A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.

A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.

Journal: Clinical and experimental rheumatology

Published: April 24, 2024

Epithelial Interleukin-1 Receptor-Like-1 Activation Is Contingent on Interleukin-33 Isoforms and Asthma-Related Receptor Variation.

Epithelial Interleukin-1 Receptor-Like-1 Activation Is Contingent on Interleukin-33 Isoforms and Asthma-Related Receptor Variation.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: February 06, 2024

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.

Journal: Annals of the rheumatic diseases

Published: December 20, 2023

Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study.

Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study.

Journal: The Lancet. Rheumatology

Published: November 21, 2022

Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis.

Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis.

Journal: Rheumatology (Oxford, England)

Published: February 02, 2022

Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis.

Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis.

Journal: Annals of the rheumatic diseases

Published: March 19, 2021

Long intergenic non-coding RNAs regulate human lung fibroblast function: Implications for idiopathic pulmonary fibrosis.

Long intergenic non-coding RNAs regulate human lung fibroblast function: Implications for idiopathic pulmonary fibrosis.

Journal: Scientific reports

Published: July 02, 2018

Serum biomarker profiles suggest that atopic dermatitis is a systemic disease.

Serum biomarker profiles suggest that atopic dermatitis is a systemic disease.

Journal: The Journal of allergy and clinical immunology

Published: July 21, 2017

Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis.

Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis.

Journal: The Journal of allergy and clinical immunology

Published: December 02, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026